A Thorough Electrocardiogram Study of Edoxaban, a Novel Factor Xa Inhibitor

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

Christian T. Ruff, Robert P. Giugliano, Elliott M. Antman et al. · American Heart Journal · 2010 · 482 citations

Medicine, Cardiology, Pharmacology +14

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

Koichiro Ogata, Jeanne Mendell‐Harary, Masaya Tachibana et al. · The Journal of Clinical Pharmacology · 2010 · 448 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

Stuart J. Connolly, Indravadan Patel, Daniel E. Salazar et al. · Thrombosis and Haemostasis · 2010 · 343 citations

Medicine, Pharmacology, Pharmacotherapy +12

DU‐176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles

Taketoshi Furugohri, K. Isobe, Yuko Honda et al. · Journal of Thrombosis and Haemostasis · 2008 · 300 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +5

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

DM Bloomfield, JT Kost, Kalyan Ghosh et al. · Clinical Pharmacology & Therapeutics · 2008 · 151 citations

Medicine, Pharmacokinetics, Pharmacology +15